PMID- 11371626 OWN - NLM STAT- MEDLINE DCOM- 20010628 LR - 20181113 IS - 0027-8424 (Print) IS - 1091-6490 (Electronic) IS - 0027-8424 (Linking) VI - 98 IP - 12 DP - 2001 Jun 5 TI - Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. PG - 6800-5 AB - Dendritic cells (DCs) play a central role in regulating immune activation and responses to self. DC maturation is central to the outcome of antigen presentation to T cells. Maturation of DCs is inhibited by physiological levels of 1alpha,25 dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] and a related analog, 1alpha,25(OH)(2)-16-ene-23-yne-26,27-hexafluoro-19-nor-vitamin D(3) (D(3) analog). Conditioning of bone marrow cultures with 10(-10) M D(3) analog resulted in accumulation of immature DCs with reduced IL-12 secretion and without induction of transforming growth factor beta1. These DCs retained an immature phenotype after withdrawal of D(3) analog and exhibited blunted responses to maturing stimuli (CD40 ligation, macrophage products, or lipopolysaccharide). Resistance to maturation depended on the presence of the 1alpha,25(OH)(2)D(3) receptor (VDR). In an in vivo model of DC-mediated antigen-specific sensitization, D(3) analog-conditioned DCs failed to sensitize and, instead, promoted prolonged survival of subsequent skin grafts expressing the same antigen. To investigate the physiologic significance of 1alpha,25(OH)(2)D(3)/VDR-mediated modulation of DC maturity we analyzed DC populations from mice lacking VDR. Compared with wild-type animals, VDR-deficient mice had hypertrophy of subcutaneous lymph nodes and an increase in mature DCs in lymph nodes but not spleen. We conclude that 1alpha,25(OH)(2)D(3)/VDR mediates physiologically relevant inhibition of DC maturity that is resistant to maturational stimuli and modulates antigen-specific immune responses in vivo. FAU - Griffin, M D AU - Griffin MD AD - Department of Internal Medicine, Division of Nephrology, Mayo Clinic and Foundation, Rochester, MN 55905, USA. griffin.matthew@mayo.edu FAU - Lutz, W AU - Lutz W FAU - Phan, V A AU - Phan VA FAU - Bachman, L A AU - Bachman LA FAU - McKean, D J AU - McKean DJ FAU - Kumar, R AU - Kumar R LA - eng GR - R56 AR027032/AR/NIAMS NIH HHS/United States GR - AR-27032/AR/NIAMS NIH HHS/United States GR - DK-25409/DK/NIDDK NIH HHS/United States GR - R01 DK058546/DK/NIDDK NIH HHS/United States GR - R01 DK025409/DK/NIDDK NIH HHS/United States GR - R01 AR027032/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. DEP - 20010522 PL - United States TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (Antigens, CD) RN - 0 (B7-1 Antigen) RN - 0 (B7-2 Antigen) RN - 0 (Cd86 protein, mouse) RN - 0 (Membrane Glycoproteins) RN - 0 (Receptors, Calcitriol) RN - 0 (Transforming Growth Factor beta) RN - FXC9231JVH (Calcitriol) SB - IM MH - Animals MH - Antigens, CD/analysis MH - B7-1 Antigen/analysis MH - B7-2 Antigen MH - Calcitriol/analogs & derivatives/*pharmacology MH - Dendritic Cells/*drug effects/physiology MH - Female MH - Male MH - Membrane Glycoproteins/analysis MH - Mice MH - Mice, Inbred C57BL MH - Receptors, Calcitriol/*physiology MH - Skin Transplantation MH - Transforming Growth Factor beta/biosynthesis PMC - PMC34433 EDAT- 2001/05/24 10:00 MHDA- 2001/06/29 10:01 PMCR- 2001/12/05 CRDT- 2001/05/24 10:00 PHST- 2001/05/24 10:00 [pubmed] PHST- 2001/06/29 10:01 [medline] PHST- 2001/05/24 10:00 [entrez] PHST- 2001/12/05 00:00 [pmc-release] AID - 121172198 [pii] AID - 1721 [pii] AID - 10.1073/pnas.121172198 [doi] PST - ppublish SO - Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6800-5. doi: 10.1073/pnas.121172198. Epub 2001 May 22.